Cathay Biotech Inc.
688065.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | CN¥22,585,384 | CN¥31,986,522 | CN¥35,694,391 | CN¥54,703,167 |
| - Cash | CN¥5,346,794 | CN¥5,390,218 | CN¥6,294,604 | CN¥9,628,544 |
| + Debt | CN¥1,860,175 | CN¥1,775,955 | CN¥1,127,348 | CN¥743,510 |
| Enterprise Value | CN¥19,098,765 | CN¥28,372,258 | CN¥30,527,136 | CN¥45,818,132 |
| Revenue | CN¥2,957,912 | CN¥2,114,175 | CN¥2,441,104 | CN¥2,363,483 |
| % Growth | 39.9% | -13.4% | 3.3% | – |
| Gross Profit | CN¥836,440 | CN¥579,227 | CN¥829,201 | CN¥837,207 |
| % Margin | 28.3% | 27.4% | 34% | 35.4% |
| EBITDA | CN¥679,846 | CN¥451,263 | CN¥671,735 | CN¥667,790 |
| % Margin | 23% | 21.3% | 27.5% | 28.3% |
| Net Income | CN¥488,962 | CN¥366,524 | CN¥553,266 | CN¥594,719 |
| % Margin | 16.5% | 17.3% | 22.7% | 25.2% |
| EPS Diluted | 0.84 | 0.63 | 0.95 | 1.43 |
| % Growth | 33.3% | -33.7% | -33.6% | – |
| Operating Cash Flow | CN¥820,929 | CN¥569,451 | CN¥803,674 | CN¥594,183 |
| Capital Expenditures | -CN¥843,313 | -CN¥1,569,781 | -CN¥4,198,356 | -CN¥1,474,675 |
| Free Cash Flow | -CN¥22,384 | -CN¥1,000,329 | -CN¥3,394,683 | -CN¥880,491 |